We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?
Read MoreHide Full Article
Key Takeaways
MED launched Trilivy as the first step in its biggest strategic shift since OPTAVIA in 2017.
MED's 10-year roadmap expands metabolic-health offerings for coaches and clients across markets.
MED supports clients using GLP-1s, transitioning off them or pursuing non-drug approaches.
Medifast, Inc. (MED - Free Report) is advancing its strategic transition toward metabolic health, with management expecting positive trends to continue through the remainder of the year. The launch of its new consumer brand, Trilivy, marks the first step in the company’s 3.0 strategy, which management describes as its biggest strategic shift since the launch of OPTAVIA in 2017.
The strategy is supported by a 10-year roadmap focused on expanding the company’s offering to coaches and clients through a comprehensive metabolic health system, while also broadening its geographic and demographic reach.
The company has made substantial progress in advancing its strategic transformation, including the launch of a new brand, a new scientific institute, an enhanced coach compensation structure and a standardized training system for coaches. Medifast sees a significant opportunity in metabolic health, with more than 90% of U.S. adults and 1.5 billion adults worldwide considered metabolically unhealthy. Furthermore, growing GLP-1 adoption has greatly increased public focus on body composition and muscle preservation.
The company is broadening its metabolic health offering while continuing to engage the GLP-1 market and beyond through its coach-led model, backed by more than 45 years of clinical and scientific heritage. Medifast’s coach-guided system addresses these specific needs by supporting clients whether they are on GLP-1 medications, transitioning off them or pursuing non-drug pathways. Its programs emphasize targeted fat loss while preserving lean mass. The company also launched the Medifast Metabolic Health Institute in July to advance metabolic health through rigorous research and evidence-based education.
Overall, Medifast’s shift toward metabolic health could open new avenues for growth as GLP-1 adoption reshapes weight management. Successful execution, however, will be crucial for translating its scientific capabilities into sustainable commercial returns.
The Zacks Rundown for MED
The Zacks Rank #2 (Buy) company's shares have gained 15.5% in the past six months against the industry’s decline of 3.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.51, lower than the industry’s average of 0.84.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal year bottom line calls for a year-over-year decline of 140.2%, whereas the same for next fiscal year earnings suggests 4.1% growth year over year.
Image Source: Zacks Investment Research
Other Stocks to Consider
Some other top-ranked stocks have been discussed below:
The Chef’s Warehouse, Inc. (CHEF - Free Report) distributes specialty food and center-of-the-plate products in the United States, the Middle East, and Canada. CHEF currently carries a Zacks Rank #1 (Strong Buy). You can seethe complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for CHEF’s current fiscal-year sales and earnings indicates growth of 10.6% and 33.7%, respectively, from the year-ago reported figures. CHEF delivered a trailing four-quarter earnings surprise of 30.4%, on average.
Darling Ingredients Inc. (DAR - Free Report) develops, produces, and sells sustainable natural ingredients from edible and inedible bio-nutrients in North America, Europe, China, South America, and internationally. DAR currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for DAR’s current fiscal-year sales and earnings implies growth of 12.8% and 926.5%, respectively, from the year-ago actuals. DAR delivered a trailing four-quarter negative earnings surprise of 38.9%, on average.
Utz Brands, Inc. (UTZ - Free Report) , together with its subsidiaries, markets, sells and distributes fresh, frozen, and dry food and non-food products to foodservice customers in the United States. UTZ currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for UTZ’s current fiscal-year sales implies growth of 3.7%, and the same for earnings implies a decline of 2.4%, from the year-ago actuals. UTZ delivered a trailing four-quarter earnings surprise of 1.8%, on average.
View the Zacks #1 Rank List
Image: Bigstock
Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?
Key Takeaways
Medifast, Inc. (MED - Free Report) is advancing its strategic transition toward metabolic health, with management expecting positive trends to continue through the remainder of the year. The launch of its new consumer brand, Trilivy, marks the first step in the company’s 3.0 strategy, which management describes as its biggest strategic shift since the launch of OPTAVIA in 2017.
The strategy is supported by a 10-year roadmap focused on expanding the company’s offering to coaches and clients through a comprehensive metabolic health system, while also broadening its geographic and demographic reach.
The company has made substantial progress in advancing its strategic transformation, including the launch of a new brand, a new scientific institute, an enhanced coach compensation structure and a standardized training system for coaches. Medifast sees a significant opportunity in metabolic health, with more than 90% of U.S. adults and 1.5 billion adults worldwide considered metabolically unhealthy. Furthermore, growing GLP-1 adoption has greatly increased public focus on body composition and muscle preservation.
The company is broadening its metabolic health offering while continuing to engage the GLP-1 market and beyond through its coach-led model, backed by more than 45 years of clinical and scientific heritage. Medifast’s coach-guided system addresses these specific needs by supporting clients whether they are on GLP-1 medications, transitioning off them or pursuing non-drug pathways. Its programs emphasize targeted fat loss while preserving lean mass. The company also launched the Medifast Metabolic Health Institute in July to advance metabolic health through rigorous research and evidence-based education.
Overall, Medifast’s shift toward metabolic health could open new avenues for growth as GLP-1 adoption reshapes weight management. Successful execution, however, will be crucial for translating its scientific capabilities into sustainable commercial returns.
The Zacks Rundown for MED
The Zacks Rank #2 (Buy) company's shares have gained 15.5% in the past six months against the industry’s decline of 3.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.51, lower than the industry’s average of 0.84.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal year bottom line calls for a year-over-year decline of 140.2%, whereas the same for next fiscal year earnings suggests 4.1% growth year over year.
Image Source: Zacks Investment Research
Other Stocks to Consider
Some other top-ranked stocks have been discussed below:
The Chef’s Warehouse, Inc. (CHEF - Free Report) distributes specialty food and center-of-the-plate products in the United States, the Middle East, and Canada. CHEF currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for CHEF’s current fiscal-year sales and earnings indicates growth of 10.6% and 33.7%, respectively, from the year-ago reported figures. CHEF delivered a trailing four-quarter earnings surprise of 30.4%, on average.
Darling Ingredients Inc. (DAR - Free Report) develops, produces, and sells sustainable natural ingredients from edible and inedible bio-nutrients in North America, Europe, China, South America, and internationally. DAR currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for DAR’s current fiscal-year sales and earnings implies growth of 12.8% and 926.5%, respectively, from the year-ago actuals. DAR delivered a trailing four-quarter negative earnings surprise of 38.9%, on average.
Utz Brands, Inc. (UTZ - Free Report) , together with its subsidiaries, markets, sells and distributes fresh, frozen, and dry food and non-food products to foodservice customers in the United States. UTZ currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for UTZ’s current fiscal-year sales implies growth of 3.7%, and the same for earnings implies a decline of 2.4%, from the year-ago actuals. UTZ delivered a trailing four-quarter earnings surprise of 1.8%, on average.